Galderma fends off Dr Reddy IPR claims

Galderma Laboratories has successfully avoided three inter partes review (IPR) petitions being instituted against a patent covering its Oracea (doxycycline, USP) drug, used to treat skin condition rosacea.

In August  2015, Dr Reddy’s Laboratories filed three IPR petitions against Galderma challenging US number 8,603,506, a patent directed to the drug.

The India-based company had already filed an Abbreviated New Drug Application seeking approval to market a generic version of Oracea, prompting Galderma to sue Dr Reddy’s at the US District Court for the District of Delaware.

Stephen Maebius, partner at law firm Foley & Lardner, which represented Galderma, said: “This represents a second attempt to invalidate a patent through the IPR process pertaining to the Oracea product.

“Following our successful defence of the first IPR attack, we are very pleased that the board denied institution of all three petitions filed against the new Oracea patent in this second wave.”